Health
Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test – News-Medical.net
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce…
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.
Avacta is developing several coronavirus tests using Affimer binders that are highly…
-
Noosa News22 hours agoADF to introduce billion-dollar drone dome over Brisbane 2032
-
General20 hours agoQueensland government strikes new deal with Bravus to defer royalties, expand Carmichael coal mine
-
Business21 hours agoMacquarie predicts more than 40% upside for this ASX 200 stock
-
Business23 hours agoInvested in IAG shares? Here are the key dates for FY26